Key result
Dopexamine treatment did not significantly improve in-hospital mortality in patients undergoing major abdominal surgery and the critically ill (RR 0.75; 95% CI 0.48-1.18; p=0.22).
Why the study?
Does dopexamine reduce in-hospital mortality in patients undergoing major abdominal surgery and in the critically ill?
Population
935 patients (pooled from 6 RCTs) undergoing major abdominal surgery and the critically ill
Design
Meta-analysis
Follow-up
in-hospital
Authors
Loading...
Dopexamine should not be used to reduce mortality in major abdominal surgery or critical illness; confirms lack of benefit in Level 1 evidence.
Meta-Analysis (n=935)
Does dopexamine reduce in-hospital mortality in patients undergoing major abdominal surgery and in the critically ill?
Relative Risk: 0.75 (95% CI 0.48–1.18)
p-value: p=0.22
Dopexamine does not significantly improve in-hospital mortality in critically ill patients or those undergoing major abdominal surgery.
Jayakumar et al. (2009) conducted a meta-analysis in Major abdominal surgery and critically ill (n=935). Dopexamine was evaluated on In-hospital mortality (relative risk 0.75, 95% CI 0.48-1.18, p=0.22). Dopexamine treatment did not significantly improve in-hospital mortality in patients undergoing major abdominal surgery and the critically ill (RR 0.75; 95% CI 0.48-1.18; p=0.22).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: